Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes
Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, Copson K, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer E, Wadleigh M, Stone R, DeAngelo D, Garcia J, Haferlach T, Lindsley C, Luskin M, Stahl M, Tothova Z. Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes. Blood 2023, 142: 999. DOI: 10.1182/blood-2023-187519.Peer-Reviewed Original ResearchAcute myeloid leukemiaDana-Farber Cancer InstituteProgression free survivalMyelodysplasia related changesMyelodysplastic syndromeOverall survivalTP53 mutationsSTAG2 mutationsRAD21 mutationsMDS/myeloproliferative neoplasmPrognostic impactClinical outcomesDana-Farber Cancer Institute cohortPrognostic impact of TP53 mutationsFollow-upDe novo acute myeloid leukemiaImpact of TP53 mutationsAllogeneic stem cell transplantationCohesin mutationsSecondary acute myeloid leukemiaRisk of leukemic transformationSubtype of myelodysplastic syndromeAnalysis of overall survivalAssociated with myelodysplastic syndromeAML-free survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply